These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23561476)

  • 21. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
    Roschewski M; Farooqui M; Aue G; Wilhelm F; Wiestner A
    Leukemia; 2013 Sep; 27(9):1920-3. PubMed ID: 23486532
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
    Herman SE; Johnson AJ
    Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review).
    Meng D; He W; Zhang Y; Liang Z; Zheng J; Zhang X; Zheng X; Zhan P; Chen H; Li W; Cai L
    Pharmacol Res; 2021 Nov; 173():105900. PubMed ID: 34547385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
    Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
    Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
    Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
    Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.
    Blunt MD; Carter MJ; Larrayoz M; Smith LD; Aguilar-Hernandez M; Cox KL; Tipton T; Reynolds M; Murphy S; Lemm E; Dias S; Duncombe A; Strefford JC; Johnson PW; Forconi F; Stevenson FK; Packham G; Cragg MS; Steele AJ
    Blood; 2015 Jun; 125(26):4032-41. PubMed ID: 25957390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
    Amrein L; Shawi M; Grenier J; Aloyz R; Panasci L
    Int J Cancer; 2013 Jul; 133(1):247-52. PubMed ID: 23238639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.
    Lafouresse F; Bellard E; Laurent C; Moussion C; Fournié JJ; Ysebaert L; Girard JP
    Blood; 2015 Sep; 126(11):1336-45. PubMed ID: 26162407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
    Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
    Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
    Wen Y; Meng L; Zhang X; Gao Q
    Expert Rev Hematol; 2022 Sep; 15(9):849-856. PubMed ID: 35920616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K/Akt/mTOR signaling by natural products.
    Huang S
    Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
    [No Abstract]   [Full Text] [Related]  

  • 38. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
    Ringshausen I; Schneller F; Bogner C; Hipp S; Duyster J; Peschel C; Decker T
    Blood; 2002 Nov; 100(10):3741-8. PubMed ID: 12393602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
    Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
    Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.